CRDL
NASDAQCardiol Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Price$1.10-0.02 (-1.79%)
01:30 PM07:45 PM
News · 26 weeks35-85%
2026-04-192026-10-11
Mix1890d
- SEC Filings9(50%)
- Other8(44%)
- Analyst1(6%)
Latest news
25 items- SECSEC Form 6-K filed by Cardiol Therapeutics Inc.6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)
- PRCardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s EfficacyOriginal 110-patient enrollment target achieved ahead of the Company's end-of-September guidance.The MAVERIC Steering Committee recommends expanding enrollment to up to 150 patients to capture sufficient events for a robust assessment of CardiolRx™'s potential to reduce recurrence risk. The recommendation follows a blinded review showing fewer-than-expected recurrences—an observation the Company views as encouraging.Topline results anticipated in mid-2027 following expanded enrollment and study completion.Existing capital expected to fund MAVERIC completion, with cash runway into Q1 2028.TORONTO, Sept. 23, 2026 /CNW/ -- Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Co
- SECSEC Form SUPPL filed by Cardiol Therapeutics Inc.SUPPL - Cardiol Therapeutics Inc. (0001702123) (Filer)
- SECAmendment: SEC Form F-10/A filed by Cardiol Therapeutics Inc.F-10/A - Cardiol Therapeutics Inc. (0001702123) (Filer)
- SECSEC Form 6-K filed by Cardiol Therapeutics Inc.6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)
- PRCardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in ProceedsProceeds strengthen balance sheet ahead of pivotal Phase III MAVERIC trial data readout in recurrent pericarditis and extends cash runway into H1 2028.TORONTO, Sept. 16, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce it has received proceeds of over USD $7 million from the exercise of outstanding common share purchase warrants. The capital raised will extend Cardiol's cash runway into H1 2028, fund operations through topline data readout from the pivotal Phase III MAVERIC trial of CardiolRx™ in recurrent pe
- SECSEC Form 6-K filed by Cardiol Therapeutics Inc.6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)
- SECSEC Form 6-K filed by Cardiol Therapeutics Inc.6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)
- SECSEC Form 6-K filed by Cardiol Therapeutics Inc.6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)
- PRCardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities CommissionTORONTO, Sept. 10, 2026 /CNW/ -- Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has filed a preliminary short form base shelf prospectus (the "Shelf Prospectus") with the securities regulatory authorities in each of the provinces and territories of Canada, together with a corresponding registration statement on Form F-10 (the "Registration Statement") with the United States Securities and Exchange Commission (the "SEC") under the U.S./Canada Multijurisdictional Disclosure System.
- SECSEC Form F-X filed by Cardiol Therapeutics Inc.F-X - Cardiol Therapeutics Inc. (0001702123) (Subject)
- SECSEC Form F-10 filed by Cardiol Therapeutics Inc.F-10 - Cardiol Therapeutics Inc. (0001702123) (Filer)
- SECSEC Form 6-K filed by Cardiol Therapeutics Inc.6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)
- PRCardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment ConferenceTORONTO, Sept. 9, 2026 /CNW/ -- Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York, NY, on September 14, 2026, at 10:30 a.m. EDT. H.C. Wainwright 28th Annual Global Investment ConferenceWhen: Monday, September 14 at 10:30 a.m. EDT.Where: Lotte New York Palace Hotel, in the Louis Room (4th Floor)A live webcast of the Fireside Chat will be accessible u
- ANALYSTB. Riley Securities initiated coverage on Cardiol Therapeutics with a new price targetB. Riley Securities initiated coverage of Cardiol Therapeutics with a rating of Buy and set a new price target of $11.00
- SECSEC Form 6-K filed by Cardiol Therapeutics Inc.6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)
- SECSEC Form 6-K filed by Cardiol Therapeutics Inc.6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)
- PRCardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth ConferenceTORONTO, Aug. 5, 2026 /CNW/ -- Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference in Boston, MA, on August 11, 2026, at 9:00 a.m. EDT. Canaccord Genuity's 46th Annual Growth ConferenceWhen: Tuesday, August 11 at 9:00 a.m. EDT.Where: InterContinental Boston Hotel, in Griffin/RobinsonA live webcast of the Fireside Chat will be accessible under "Events & Presentations" in the
- SECSEC Form 6-K filed by Cardiol Therapeutics Inc.6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)
- PRCardiol Therapeutics' Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association• Peer-reviewed JAHA publication strengthens the foundation for Cardiol's pivotal Phase III MAVERIC trial as enrollment nears completion.TORONTO, July 14, 2026 /CNW/ -- Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today announced the publication of its Phase II MAvERIC study results in the Journal of the American Heart Association ("JAHA"). The publication comes as the pivotal Phase III MAVERIC trial nears full patient enrollment. The publication describes clinical findings in which C
- SECSEC Form 6-K filed by Cardiol Therapeutics Inc.6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)
- PRCardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision SummitTORONTO, July 9, 2026 /CNW/ - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at the B. Riley Securities Mind, Muscle & Vision Summit in Boston, MA, on July 16, 2026, at 12:20 p.m. EDT. B. Riley Securities Mind, Muscle & Vision SummitWhen: Thursday, July 16 at 12:20 p.m. Eastern Time.Where: InterContinental Boston Hotel, in Abigail Adams Salon BAbout Cardiol TherapeuticsCardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) i
- SECSEC Form 6-K filed by Cardiol Therapeutics Inc.6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)
- PRCardiol Therapeutics Reports Results of 2026 Annual General Meeting of ShareholdersTORONTO, June 25, 2026 /CNW/ - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, announces the results from its Annual General Meeting of Shareholders (the "AGM") held virtually via live audio webcast on June 24, 2026. Shareholders voted overwhelmingly in favour of all Management resolutions proposed in the Company's Management Information Circular dated May 7, 2026. Resolutions proposed and approved at the AGM were:The election of the foll
- SECSEC Form 6-K filed by Cardiol Therapeutics Inc.6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)
CRDL FAQ
6 questionsWhat does Cardiol Therapeutics Inc. do?
Cardiol Therapeutics Inc., a clinical-stage biotechnology company, focuses on the research and development of anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, an ultra-pure and high concentration cannabidiol oral formulation for the treatment of in hospitalized COVID-19 patients with a prior history of risk factors for CVD; and has completed phase I clinical trials for the treatment of acute myocarditis and other inflammatory heart disease. The company is also developing a proprietary subcutaneous formulation of cannabidiol to...Where does CRDL stock trade?
Cardiol Therapeutics Inc. (CRDL) is listed on NASDAQ.What sector and industry is CRDL in?
Cardiol Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about CRDL?
Cardiol Therapeutics Inc. has had 7 recent analyst actions on file. The most recent action was from B. Riley Securities: Buy with a $1100.00 price target on 2026-08-26. Recent price targets range from $700.00 to $1100.00.What companies are similar to CRDL?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare CRDL side-by-side with any of them on Quantisnow.How can I track CRDL on Quantisnow?
Quantisnow aggregates Cardiol Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CRDL to receive live email and push alerts on every new disclosure.